Thomas Groennebaek

Principal Clinical Scientist, Clinical Drug Development, NMD Pharma

[Science Translational Medicine @ScienceTM]

A small molecule inhibitor that targets the chloride channel CIC-1 can partially restore skeletal muscle function, strength, and motor neuron-muscle fiber crosstalk in rats with #MyastheniaGravis, and proves safe in patients in a phase 1 trial. @NMDPharma https://t.co/uuCHZEpbjo

[NMD Pharma @NMDPharma]

We’re excited to announce a new #publication in @ScienceTM which establishes CIC-1 inhibition as a novel therapeutic approach to improve muscle function and symptoms of #MG and, potentially, in other #NeuromuscularDiseases. For more: https://t.co/9ITD2JtCCL

[NMD Pharma @NMDPharma]

#NMDPharma will be presenting a talk and a poster this week at the #SMACongress2024, held from 14-16 March in Ghent. We look forward to hearing about the latest developments in the field of #SMA research and sharing a #clinical update. Find out more https://t.co/WBbEf3AOHz

[NMD Pharma @NMDPharma]

Today we are able to announce positive topline data from our Phase I/IIa clinical trial of NMD670 in patients with #MyastheniaGravis https://t.co/WBbEf3Bmx7

#NMDPharma #clinicaldata #myastheniagravis #clinicaltrial #neuromusculardisease #biotech #healthcare

[Thomas Groennebaek @tgroennebaek]

@bc_porter @NMDPharma @SMA_UK_ @MDUK_News We appreciate your support Ben! 👍☺️ many thanks again

[NMD Pharma @NMDPharma]

This #MyastheniaGravisAwarenessMonth @tgroennebaek caught up with Ulrik, an inspirational #MyastheniaGravis patient who shared his difficulty in getting a diagnosis and the power of patient advocacy groups.

Read the Q&A on our website here: https://t.co/lta1tRhGC6

#NMDPharma

[Thomas Groennebaek @tgroennebaek]

@TMadenWilkinson @TLexercise @MVFranchi @DrMark_Faghy Thanks a lot for arranging Tom. Great season

[ICFSRcongress @ICFSRcongress]

SYMPOSIUM @ICFSRcongress
NEUROMUSCULAR JUNCTION TRANSMISSION FAILURE IN SARCOPENIA
W. David Arnold, Columbus, OH, (USA) and Thomas Holm Pedersen, PhD, NMD Pharma A/S, Aarhus, (Denmark) answer questions from the floor

[NMD Pharma @NMDPharma]

We are hiring! NMD Pharma is looking for a dedicated in vivo Laboratory Technician for our Research department. What is NMD Pharma? NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases. Please have a look here: https://t.co/9mvbc3HrH0
#Hiring #LabTech

[Thomas Groennebaek @tgroennebaek]

@ICFSRcongress @NMDPharma @DaveArnoldLab @NMDpharmaThomas @T_Kongstad @stine_krag

[ICFSRcongress @ICFSRcongress]

@ICFSRcongress

IMPORTANT SYMPOSIUM
NEUROMUSCULAR JUNCTION TRANSMISSION FAILURE IN SARCOPENIA
D Arnold, Columbus, (USA) - Brian C. Clark,Ohio University, (USA) - T. Holm Pedersen,(Denmark)
ICFSR 2022 - 20-22 April in Boston (USA)
Final Program online!
https://t.co/qrGI3S6cJ3

[Kim Ryun Drasbek @KimRyunDrasbek]

In this translational study, we see beneficial effects of extracellular vesicles in hypoxic cells and an accumulation of the vesicles in the ischemic hemisphere of tMCAO stroke mice. Thanks to all the great people making this study possible.

[NMD Pharma @NMDPharma]

Congrats to our collaborators at @OhioState on their recent publication in BMJ Neurology Open. The study by Professors Elsheikh and @DaveArnoldLab highlights the high unmet medical need for novel treatments to address NMJ transmission defects. https://t.co/rkAKz9KK6h @bmj_company

[Dave Arnold @DaveArnoldLab]

NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease. Super excited about this study and collaboration! Hopefully we can start filling the huge gap for CMT patients. https://t.co/46YbY3YbDU

[Thomas Groennebaek @tgroennebaek]

@JJakobsgaard @japplphysiol @VissingKristian Stærkt Jesper. Link til artikel?

[Stephen Patterson @stephen_patt]

Myself, @Dr_Burr & @S_Warmington recently edited research topic with @FrontPhysiol called: Blood Flow Restriction: Rehabilitation to Performance. Over the next few weeks, I will upload a video abstract for each paper accepted to show the great work carried out by the researchers.

[Exercise and Sport Sciences Reviews @ESSRonline]

Low-load blood flow restricted resistance exercise may have the ability to produce concurrent skeletal muscle myofibrillar, mitochondrial, and microvascular adaptations.
https://t.co/28bpKgGdXG

[Thomas Groennebaek @tgroennebaek]

#PLOSONE: Differences in intrinsic aerobic capacity alters sensitivity to ischemia-reperfusion injury but not cardioprotective capacity by ischemic preconditioning in rats https://t.co/WavYjJRP6j

[Kelsey Fisher-Wellman, PhD @KFW_Lab]

Attention all #mitochondriacs

Check out our latest work in @SciReports where we describe a method for quantifying mitochondrial content and intrinsic OXPHOS efficiency using mass spectrometry, respirometry and fluorescence https://t.co/8jRYvYECHR.

See 👇 for details. 1/

[Exercise and Sport Sciences Reviews @ESSRonline]

Low-load blood flow restricted resistance exercise may have the ability to produce concurrent skeletal muscle myofibrillar, mitochondrial, and microvascular adaptations. https://t.co/gn5yxqpdKZ